Solventum Corp(SOLV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 10.71 | EPS (ttm) | 8.18 | Insider Own | 15.06% | Shs Outstand | 170.1M | Perf Week | -4.62% |
| Market Cap | 14.92B | Forward P/E | 12.01 | EPS next Y | 1.94% | Insider Trans | 0.01% | Shs Float | 144.6M | Perf Month | 4.22% |
| Enterprise Value | 19.80B | PEG | 1.22 | EPS next Q | 1.34 | Inst Own | 76.68% | Short Float | 2.4% | Perf Quarter | 8.29% |
| Income | 1.43B | P/S | 1.8 | EPS this Y | 17.18% | Inst Trans | -1.38% | Short Ratio | 2.93 | Perf Half Y | 29.62% |
| Sales | 8.31B | P/B | 3.11 | EPS next 5Y | 9.84% | ROA | 9.78% | Short Interest | 3.47M | Perf YTD | 10.61% |
| Book/sh | 28.22 | P/C | 37.02 | EPS past 3/5Y | 4.51% 1.23% | ROE | 33.96% | 52W High | -6.91% ($94.16) | Perf Year | 23.07% |
| Cash/sh | 2.37 | P/FCF | - | Sales past 3/5Y | 0.79% 0.47% | ROIC | 14.97% | 52W Low | 40.51% ($62.38) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 16.73 | EPS Y/Y TTM | 277.21% | Gross Margin | 55.21% | Volatility(W/M) | 1.94% 2.34% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.38 | Sales Y/Y TTM | -1.18% | Oper. Margin | 8.48% | ATR (14) | 2.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.74 | EPS Q/Q | 3.35% | Profit Margin | 17.26% | RSI (14) | 46.99 | Recom | 2.41 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.02 | Sales Q/Q | 1.19% | SMA20 | -2.48% ($89.88) | Beta | 0.69 | Target Price | $95.83 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/8/5 | SMA50 | 3.52% ($84.67) | Rel Volume | 0.6 | Prev Close | $90.03 |
| Employees | 20000 | LT Debt/Eq | 1 | EPS/Sales Surpr. | 33.89% 2.55% | SMA200 | 13.01% ($77.56) | Avg Volume(3M) | 1.19M | Price | $87.65 |
| IPO | 2024/3/26 | Option/Short | Yes/Yes | Trades | 12617 | Volume | 708,471 | Change | -2.64% |
Company
SOLV is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Solventum is a U.S. healthcare company that provides medical and surgical supplies, dental solutions, and health information systems. It was spun off from 3M in 2024 and listed as an independent company, specializing in medical devices and consumables, with a high proportion of its revenue coming from recurring purchases of consumable products.
Over the past 1 year, on the higher side
7% below its 1-year high.
SOLV makes money exceptionally well
8.48% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.2% this year.
Tap to view numbers
The price looks about right
Trading at 10.7 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 76.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
CSD 0.04%
NEWZ 0.03%
FXH 0.02%
PZLV 0.02%
RSPH 0.02%It ranks #4 in the industry
Based on market cap of $15B.
SOLV $15B PER 10.7
ISRG $127B PER 41.3
BDX $48B PER 53.2
MDLN $43B PER 38.0
FAQ
What kind of company is SOLV?
SOLV belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of SOLV?
The market cap of SOLV is approximately $14.9B, ranking 724 within its sector.
What is the P/E ratio of SOLV?
SOLV has a P/E ratio of approximately 10.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SOLV?
SOLV has recorded a 52-week high of $94.16 and a low of $62.38.
